HC Wainwright Reiterates Buy Rating for PolyPid (NASDAQ:PYPD)

PolyPid (NASDAQ:PYPD)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $13.00 price target on the stock. HC Wainwright’s price target indicates a potential upside of 183.22% from the company’s previous close. HC Wainwright also issued estimates for PolyPid’s FY2028 earnings at $0.21 EPS and FY2030 earnings at $4.02 EPS.

Several other research firms also recently commented on PYPD. Wall Street Zen raised shares of PolyPid from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Weiss Ratings restated a “sell (d-)” rating on shares of PolyPid in a research note on Monday, December 29th. Roth Mkm reduced their target price on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Finally, Citigroup reiterated a “market outperform” rating on shares of PolyPid in a report on Monday, December 1st. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.25.

PolyPid Stock Down 0.6%

PYPD opened at $4.59 on Wednesday. The business has a fifty day moving average of $4.36 and a 200 day moving average of $3.80. PolyPid has a 52-week low of $2.30 and a 52-week high of $5.12. The stock has a market cap of $72.98 million, a P/E ratio of -2.03 and a beta of 1.52.

PolyPid (NASDAQ:PYPD) last released its earnings results on Wednesday, February 11th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). Equities analysts anticipate that PolyPid will post -1.79 EPS for the current fiscal year.

Hedge Funds Weigh In On PolyPid

Institutional investors have recently bought and sold shares of the business. Lumbard & Kellner LLC purchased a new stake in PolyPid during the second quarter worth $135,000. AIGH Capital Management LLC raised its position in shares of PolyPid by 27.0% in the 2nd quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock worth $4,215,000 after acquiring an additional 253,727 shares in the last quarter. BNP Paribas Financial Markets raised its position in shares of PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after acquiring an additional 3,500 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of PolyPid during the 4th quarter worth $66,000. Finally, HighTower Advisors LLC bought a new stake in PolyPid during the fourth quarter valued at about $44,000. 26.47% of the stock is owned by hedge funds and other institutional investors.

PolyPid News Summary

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” and modeled aggressive long-term upside (FY2028 EPS $0.21; FY2030 EPS $4.02) and set a $13 price target — signaling institutional conviction around D-PLEX₁₀₀ commercialization and large upside vs current levels. HC Wainwright research / MarketBeat
• Positive Sentiment: Company update: PolyPid says it is in advanced-stage U.S. partnership discussions for D-PLEX₁₀₀ — management and analysts flagged a “big 2026 catalyst” tied to commercialization progress, which could materially re-rate the stock if a partner deal or commercial plan is announced. GlobeNewswire press release
• Neutral Sentiment: Earnings call tone was mixed — management highlighted strategic and development advances for D-PLEX₁₀₀ but also discussed operational challenges and timing uncertainties around partnerships/launch, making near-term stock reaction dependent on concrete partnership milestones. TipRanks earnings call summary
• Negative Sentiment: Q4 results disappointed: EPS of -$0.41 missed the -$0.34 consensus. The company remains loss-making and consensus models a full-year EPS around -$1.79, keeping short-term valuation under pressure until revenue/partnership visibility improves. MarketBeat earnings report

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.